Pharma DECODED
Latest edition: 20 May 2024
Share newsletter
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Spotlight
Sanders issues warning to Novo Nordisk amid GLP-1 drug price investigation
Senator Sanders took another swipe at the US prices of Novo Nordisk’s blockbuster GLP-1 receptor agonist drugs Ozempic and Wegovy.
Latest news
Pfizer wins cancer drug patent case against AstraZeneca
The jury found that AstraZeneca's Tagrisso violated Pfizer's Wyeth unit's patent rights.
J&J expands dermatology portfolio with $850m Proteologix acquisition
J&J has gained access to several bispecific antibody programmes, including the Phase I-ready asset PX128 for atopic dermatitis and asthma.
GLP-1 receptor agonists market grows
Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic or Wegovy (semaglutide), Saxenda (liraglutide), or Zepbound (tirzepatide), have become increasingly popular in promoting weight loss.
Read Press Release
Vividion Therapeutics, Inc., a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, announced that seasoned financial executive Patricia “Patty” Allen has joined Vividion as acting chief financial officer
EMA recommends suspension of 17-OHPC medicines in EU
The development comes after the regulator found increased cancer risk in people exposed to 17-OHPC.
FDA grants IND clearance for Drug Farm's ROSAH syndrome trial
The trial will evaluate the safety, pharmacokinetics, and efficacy of DF-003 in individuals affected by the ROSAH condition.
Vicore to kickstart Phase IIb IPF trial for buloxibutid
Vicore Pharma will initiate the Phase IIb trial by the end of H1 2024.
How patient advocacy can lead to more successful and meaningful clinical trials
Kelly Franchetti discusses the evolving role of patient advocates and the key relationships needed to advance drug development.
Erasca trims workforce and pipeline to focus on KRAS and molecular glues
Erasca has made operational cuts while licensing a molecular glue therapy and a KRAS inhibitor for $22.5m upfront.
In our previous edition
Pharma Decoded
Patient access to medicines must be the focus of US drug pricing policy
17 May 2024
Pharma Decoded
KRAS inhibitors: The next frontier beckons
16 May 2024
Pharma Decoded
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
15 May 2024
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer